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Background: Previous studies have reported that nuclear receptor subfamily 5, group A, 
member 2 (NR5A2) polymorphisms (rs3790843 G.A, rs3790844 T.C, rs12029406 C.T) are 
associated with the risk of pancreatic cancer. However, the results of epidemiological investiga-
tions are still controversial. In order to explore its potential attributing factors, we pooled the 
updated literatures to evaluate the association between NR5A2 polymorphism and the risk of 
pancreatic cancer in this meta-analysis.
Materials and methods: Databases such as PubMed, Google Scholar and China National 
Knowledge Infrastructure were searched for eligible articles following strict inclusion and exclu-
sion criteria (updated to November 18, 2017). Odds ratios (ORs) and 95% CIs were computed to 
assess the intensity of association. In addition, heterogeneity, sensitivity analysis and publication 
bias were explored. All statistical analyses were conducted by STATA 14.0.
Results: Our results showed that the rs3790843 (GA vs GG: OR=0.86, CI=0.76–0.98, 
P=0.992; GA+AA vs GG: OR=0.83, CI=0.73–0.94, P=0.950; A vs G: OR=0.85, CI=0.78–0.93, 
P=0.802), rs3790844 (CC vs TT: OR=0.65, CI=0.54–0.78, P=0.617; CC vs TT+CT: 
OR=0.73, CI=0.62–0.85, P=0.742; C vs T: OR=0.78, CI=0.73–0.84, P=0.555) and rs12029406 
(TT vs CC: OR=0.73, CI=0.61–0.89, P=0.483; TT vs CC+CT: OR=0.78, CI=0.66–0.92, 
P=0.648; T vs C: OR=0.87, CI=0.79–0.95, P=0.837) polymorphisms were associated statisti-
cally with the risk of pancreatic cancer. Furthermore, the results of subgroup analysis showed 
that rs3790843 and rs3790844 polymorphisms were especially related to the risk of pancreatic 
cancer in Caucasian population.
Conclusion: Our results revealed that NR5A2 may have a protective effect on pancreatic 
cancer. However, more well-designed researches are needed to verify the relationship between 
NR5A2 polymorphisms and the risk of pancreatic cancer.
Keywords: NR5A2, polymorphism, rs3790844, pancreatic cancer, meta-analysis
Introduction
Pancreatic cancer is a highly aggressive and malignant tumor, in which the most 
frequent type of tissue is ductal adenocarcinoma.1 In the USA, about 85% of pancreatic 
cancer patients had already developed metastasized or unresectable lesions at the time 
of diagnosis and were expected to live 12 months at most.2,3 The mortality rates are 
still rising in our country (China).4 Although the cause of pancreatic cancer is not yet 
clear, its high mortality rate is closely related to the biologic characteristics of the 
tumor and the genetic factors.5 It has been shown that 10% of pancreatic cancer is 
caused by genetic mutations.6 Meanwhile, levels of molecular markers can be used to 
predict the prognosis of pancreatic cancer.7
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Nuclear receptor subfamily 5, group A, member 2 
(NR5A2), also called as liver receptor homolog-1, is a mem-
ber of orphan nuclear hormone receptors, which is highly 
expressed in the pancreas, liver, intestine and ovary and is 
involved in the balance of cholesterol, steroidogenesis and 
bile acid in the body.8,9 NR5A2 is located on chromosome 
1q32.1, which is reported to play an important role in the 
stability of the pancreatic acinar cell.10 Murtaugh reported that 
the lack of NR5A2 will promote the mutation of Kras gene 
which can accelerate deterioration of pancreatic cancer.11 
Human genome-wide association studies have suggested that 
there is a significant association between single-nucleotide 
polymorphisms (SNPs) of NR5A2 and the risk of pancreatic 
cancer.12 Among these SNPs, rs3790844 is the focus of 
our study.
Located in the first intron of NR5A2, the SNP rs3790843 
is characterized by G.A, while rs3790844 is characterized 
by T.C.13 The SNP rs12029406, which is characterized by 
C.T, might influence the receptor activity, which, in turn, 
can change the disease risk and survival.20 After searching 
the databases, we found five articles focusing on the associa-
tion between their polymorphisms and the risk of pancreatic 
cancer.18–22 In order to get rid of the limitations of a single 
trial and gain a result of comprehensive meaning, we com-
bined the five studies using meta-analysis to confirm whether 
rs3790843, rs3790844 and rs12029406 polymorphisms 
would affect the risk of pancreatic cancer, which has never 
been done before.
Materials and methods
literature search
We searched for relevant publications using the following 
words and terms: “NR5A2”, “polymorphism/variety” and 
“pancreatic cancer/pancreatic ductal adenocarcinoma” in 
databases such as PubMed, Google Scholar and the China 
National Knowledge Infrastructure, and all literatures were 
published before November 18, 2017. References to these 
literatures were also screened in order to prevent loss of any 
valuable data.
inclusion and exclusion criteria
Eligible studies were selected according to the following 
inclusion criteria: 1) focusing on the association between 
NR5A2 polymorphism and the risk of pancreatic cancer, 2) a 
case–control study, 3) providing available and sufficient data 
of genotype frequencies for calculating an odds ratio (OR) 
with 95% CI and 4) distribution of the genotype in case and 
control groups was in Hardy–Weinberg equilibrium (HWE). 
The exclusion criteria were as follows: 1) non-case–control, 
pure cell or animal studies, 2) not related to the risk of 
pancreatic cancer and 3) not containing useful genotype 
frequency data.
Data extraction
Two authors (Q Chen, H Yuan) independently screened the 
literatures, extracted the relevant information and finally 
discussed disagreement. All the data were recorded in the 
standard form: first author’s name, year of publication, 
country of population, control source, genotypic methods, 
number of genotypes in case–control groups and result of 
the HWE test. We set the total data of the case and control 
groups .1,000 as “sample size Y” and ,1,000 as “sample 
size N”. In addition, we classified the populations from USA, 
England and Germany as Caucasian, while those from China 
and Japan were identified as Asian for subgroup analysis.
genetic model
A is the mutant allele of rs3790844 which includes two alleles 
G and A, C is the mutant allele of rs3790844 and T is the 
mutant allele of rs12029406. We selected the heterozygous 
model (GA vs GG or CT vs TT or CT vs CC), homozy-
gous model (AA vs GG or CC vs TT or TT vs CC), dominant 
model (GA+AA vs GG or CT+CC vs TT or CT+TT vs CC), 
recessive model (AA vs GG+GA or CC vs TT+CT or TT vs 
CC+CT) and allele model (A vs G or C vs T or T vs C) for 
further meta-analysis.
statistical analysis
Our meta-analysis was conducted by Stata software (version 
14.0; StataCorp LP, College Station, TX, USA). To assess 
the strength of association between NR5A2 polymorphism 
and the risk of pancreatic cancer, we calculated the OR 
together with 95% CI for each genetic model. Furthermore, 
we evaluated the heterogeneity by Cochran’s Q-statistic.14 
A P-value ,0.1 indicated significant heterogeneity. Another 
method to evaluate the heterogeneity is I2, which represents 
the percentage of variance across the whole study. In general, 
values of I2 ,25% represent “low heterogeneity”, while 
values .75% represent “high heterogeneity”.15 Statistically, 
I2 .50% indicates that the heterogeneity is significant and 
the random-effects model was chosen.16 Otherwise, the 
fixed-effects model was used.17 Moreover, data with similar 
characteristics such as source of control (HB/PB), sample 
size (Y/N) and ethnicity of the population (Asian/Caucasian) 
were used for subgroup analysis.
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Sensitivity analyses were performed to assess the stability 
of the studies on the pooled ORs. A single study in the 
analysis was omitted each time to calculate the outcomes 
again. Publication bias was evaluated by using Begg’s test 
and Egger’s test, and P,0.05 indicated significant bias. 
HWE was checked by the goodness-of-fit chi-square test, and 
P.0.05 indicated the genetic balance of the population and 
that the data were from the same Mendelian group.
Results
literature selection and study 
characteristics
The procedure of literature screening is shown in Figure 1. 
We found 24 articles related to NR5A2 polymorphism from 
PubMed, Google Scholar and China National Knowledge 
Infrastructure. According to the inclusion and exclusion 
criteria, 19 articles were excluded. Among the selected 
articles, 3 articles were reviews, 6 articles were not associated 
with the risk of pancreatic cancer and the other 10 articles 
lacked usable data for estimating an OR with 95% CI. 
Ultimately, a total of five literatures were included in the 
meta-analysis.18–22 Among them, four studies containing 
2,212 cases and 2,932 controls surveyed the association 
between rs3790843 G.A and pancreatic cancer risk, five 
articles on the relation between rs3790844 T.C and pancre-
atic cancer risk included 4,191 cases and 5,133 controls, and 
three publications containing 1,822 cases and 2,510 controls 
explored the correlation of rs12029406 C.T with pancreatic 
cancer risk. One of the articles studied the association 
between NR5A2 polymorphism and the risk of pancreatic 
cancer not only from England but also from Germany with 
different genotyping methods.20 Data for different controls 
from the same study were considered as a separate data set, 
which can be used for all analyses. Study characteristics of 
each literature are shown in Table 1.
nr5a2 rs3790843, rs3790844 and 
rs12029406 polymorphisms
We first analyzed the association between rs3790843, 
rs3790844 and rs12029406 polymorphisms and the risk of 
pancreatic cancer in the overall population, and the forest 
plots are shown in Figures 2–4. Then, in order to explain 
the relationship between their polymorphisms and the risk of 
pancreatic cancer, we also performed the subgroup analyses 
by control source, sample size and ethnicity. All results are 
presented in Table 2 in detail.
Overall effects for meta-analysis
Of the studies, two articles suggested the association 
between rs3790843 G.A and pancreatic cancer risk, three 
studies revealed an obvious association between rs3790844 
T.C and pancreatic cancer risk and one research showed 
the association between rs12029406 C.T and pancreatic 
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3XE0HGQ 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&1.,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Q 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Q 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Q 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Figure 1 Flowchart of the literature selection process.
Abbreviation: cnKi, china national Knowledge infrastructure.
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Figure 2 Forest plots of pancreatic cancer risk associated with nr5a2 rs3790843 g.a polymorphism.
Notes: (A) ga vs gg; (B) ga+aa vs gg; (C) a vs g.
Abbreviation: Or, odds ratio.
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Figure 3 Forest plots of pancreatic cancer risk associated with nr5a2 rs3790844 T.c polymorphism.
Notes: (A) cc vs TT; (B) cc vs TT+cT; (C) c vs T. Weights are from random-effects analysis.
Abbreviation: Or, odds ratio.
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Figure 4 Forest plots of pancreatic cancer risk associated with nr5a2 rs12029406 c.T polymorphism.
Notes: (A) TT vs cc; (B) TT vs cc+cT; (C) T vs c.
Abbreviation: Or, odds ratio.
cancer risk. After analyzing the existing data, we found a 
significant association between rs3790843 polymorphism 
(GA vs GG: OR=0.86, CI=0.76–0.98, P=0.992; GA+AA vs 
GG: OR=0.83, CI=0.73–0.94, P=0.950; A vs G: OR=0.85, 
CI=0.78–0.93, P=0.802; Figure 2), rs3790844 polymor-
phism (CC vs TT: OR=0.65, CI=0.54–0.78, P=0.617; CC 
vs TT+CT: OR=0.73, CI=0.62–0.85, P=0.742; C vs T: 
OR=0.78, CI=0.73–0.84, P=0.555; Figure 3) and rs12029406 
polymorphism (TT vs CC: OR=0.73, CI=0.61–0.89, P=0.483; 
TT vs CC+CT: OR=0.78, CI=0.66–0.92, P=0.648; T vs C: 
OR=0.87, CI=0.79–0.95, P=0.837; Figure 4) and the risk of 
pancreatic cancer susceptibility.
subgroup analysis for control source
Subgroup analysis was stratified by control sources. Statis-
tically significant association between rs3790843 (GA vs 
GG: OR=0.84, CI=0.71–0.99, P=0.944; GA+AA vs GG: 
OR=0.80, CI=0.68–0.94, P=0.737; A vs G: OR=0.83, 
CI=0.74–0.93, P=0.934; Figure S1) and rs3790844 (CC 
vs TT: OR=0.61, CI=0.49–0.74, P=0.495; CC vs TT+CT: 
OR=0.69, CI=0.58–0.82, P=0.718; C vs T: OR=0.76, 
CI=0.70–0.82, P=0.559; Figure S2) polymorphisms with 
the risk of pancreatic cancer was detected in hospital-based 
studies under five genetic models.
subgroup analysis for sample size
The sample size with sufficient statistical capacity is critical 
to the study and for the relationship between polymorphisms 
and the risk of cancer. We set the total data .1,000 as “Y” 
and ,1,000 as “N”. Statistically significant association 
between rs3790843 (GA vs GG: OR=0.85, CI=0.75–0.98, 
P=0.793; GA+AA vs GG: OR=0.82, CI=0.72–0.94, P=0.745; 
A vs G: OR=0.84, CI=0.76–0.93, P=0.757; Figure S3) and 
rs3790844 (CC vs TT: OR=0.66, CI=0.54–0.82, P=0.344; 
CC vs TT+CT: OR=0.73, CI=0.63–0.85, P=0.411; C vs T: 
OR=0.78, CI=0.72–0.85, P=0.300; Figure S4) polymor-
phisms and the risk of pancreatic cancer was also detected 
in “Y”-based studies under five genetic models.
subgroup analysis for ethnicity
Subgroup analysis was stratified by ethnicity. The relationship 
between rs3790843 (GA vs GG: OR=0.86, CI=0.76–0.98, 
P=0.912; GA+AA vs GG: OR=0.83, CI=0.73–0.94, P=0.843; 
A vs G: OR=0.85, CI=0.77–0.93, P=0.798; Figure 5) and 
rs3790844 (CC vs TT: OR=0.67, CI=0.55–0.82, P=0.491; 
CC vs TT+CT: OR=0.73, CI=0.60–0.89, P=0.575; C vs T: 
OR=0.78, CI=0.73–0.85, P=0.404; Figure 6) polymorphisms 
and the risk of pancreatic cancer was detected from the data 
of Caucasian population.
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Figure 5 subgroup analysis of ethnicity for nr5a2 rs3790843 g.a polymorphism and pancreatic cancer risk.
Notes: (A) ga vs gg; (B) ga+aa vs gg; (C) a vs g.
Abbreviation: Or, odds ratio.
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Notes: (A) cc vs TT; (B) cc vs TT+cT; (C) c vs T. Weights are from random-effects analysis.
Abbreviation: Or, odds ratio.
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heterogeneity test
Based on the Cochran’s Q-statistic, all the data showed 
nonsignificant heterogeneity under five genetic models 
(Table 2).
sensitivity analysis
In order to compare the differences and assess the sensitivity, 
a single study in the analysis was omitted each time to calcu-
late the outcomes again. The pooled ORs were not influenced 
significantly, which indicated our results of this meta-analysis 
were stable (Figure S5).
Publication bias analysis
To evaluate the publication bias of the publications, Begg’s 
test and Egger’s test were performed. The funnel plots of 
five genetic models whose shapes were roughly symmetrical 
suggested no significant publication bias (figure not shown). 
Moreover, the results shown in Table 3 indicate that our 
results were reliable.
Discussion
As a highly malignant disease, pancreatic cancer is the fourth 
leading cause of cancer death in the USA.23 Most patients 
would have already progressed to an advanced stage with 
a poor cure rate when diagnosed. Surgical treatment is still 
the first choice to cure pancreatic cancer up to now, but only 
15%–20% of patients have the opportunity to take it up.24,25 
What is worse, despite surgical resection, the majority of 
these patients would die from recurrence or metastasis in 
2 years.26 Radiotherapy and chemotherapy, such as gemcit-
abine (Eli Lilly and Company, Indianapolis, IN, USA) or 
molecular-targeted drugs, are recommended for patients 
lacking the opportunity to undergo surgery.27,28 Disappoint-
ingly, the efficacy of these drugs to increase the survival rate 
is barely observed and unexplainable drug resistance comes 
up. Different from other cancers, the 5-year survival rate of 
pancreatic cancer has changed just a little in the past four 
decades (as low as 6%).29 It has been shown that genetic fac-
tors play an important role in the development, progression 
and prognosis of pancreatic cancer.7,30,31 Exploring the 
genetic background of pancreatic cancer is instructive to 
find out some targets which can help in early diagnosis and 
judge the prognosis of pancreatic cancer.
Previous studies have shown that NR5A2, which is also 
known as liver receptor homolog-1, is an important regulator 
of pancreatic exocrine function.32 Lack of NR5A2, combined 
with pancreas-specific transcription factor 1 causes instabil-
ity of pancreatic acinar cells, which increases the pancreatic 
injury and then causes mutations in the Kras gene.10,32–34 As 
we all know, mutation of Kras is the earliest event in deterio-
ration of pancreatic cancer.11 We integrated the results of five 
studies and found a negative link between NR5A2 rs3790844 
polymorphism and the risk of pancreatic cancer. However, 
histologic examinations show that NR5A2 is overexpressed 
in tumor tissues, which is quiet puzzling.35 Although the 
mechanism is not clear, it does not deny our conclusion that 
NR5A2 is a protective factor for early pancreatic cancer. 
Here, we put forward several possible explanations for dis-
cussion. Overexpression of NR5A2 is also closely related to 
diabetes and hyperlipidemia, which are the important risk 
factors for pancreatic cancer, and has a positive effect on 
mutation of Kras later in pancreatic cancer progression.11,36,37 
Moreover, NR5A2 also contributes to other tumors. For 
instance, NR5A2 was reported to be involved in the metabo-
lism of glutamine to induce hepatocellular carcinoma, while 
it also induces the expression and transcription of ERα and 
mediates the secretion of estrogen to affect the progression 
of breast cancer.38–40 In addition, NR5A2 is overexpressed 
in colon cancer and osteosarcoma cells.41,42 Recently, many 
studies have reported the relationship between the NR5A2 
rs3790843, rs3790844 and rs12029406 polymorphisms and 
the risk of cholangiocarcinoma, gastric cancer and pancreatic 
cancer without consistent results.13,18–22,43 In order to clarify 
the association, we integrated the data of pancreatic cancer 
for the meta-analysis.
The polymorphism was observed to be related with pan-
creatic cancer in hospital-based studies, but not in population-
based studies in the subgroup analysis by the control source. 
Table 3 The results of Begg’s and egger’s tests
Risk model rs3790843 rs3790844 rs12029406
Begg’s test Egger’s test Begg’s test Egger’s test Begg’s test Egger’s test
Z P-value Z P-value Z P-value t P-value Z P-value t P-value
heterozygous 0.73 0.462 1.22 0.311 0.38 0.707 0.89 0.426 1.02 0.308 −2.91 0.101
homozygous 1.22 0.221 2.76 0.070 0.00 1.000 0.92 0.408 0.34 0.734 −0.81 0.501
Dominant 0.24 0.806 0.76 0.503 0.38 0.707 0.36 0.735 1.70 0.089 −3.05 0.093
recessive 0.73 0.462 1.28 0.292 1.50 0.133 2.35 0.079 0.34 0.734 0.50 0.668
allele 1.22 0.221 2.45 0.091 0.75 0.452 1.55 0.196 0.34 0.734 −0.99 0.428
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Unsurprisingly, a larger sample bounded by 1,000 was more 
credible than a smaller sample in the relationship between 
them and cancer, which suggested that future research should 
require a larger sample size. Moreover, the subgroup analysis 
by ethnicity was also performed. The association between 
rs3790843 and rs3790844 polymorphisms and the risk of 
pancreatic cancer in Caucasian population under all genetic 
models was statistically significant; however, this was not 
found in the Asian population. Different genetic background 
or different lifestyles may lead to this difference between 
them and the total population.
As far as we know, this is the first meta-analysis of 
the association between NR5A2 (rs3790843, rs3790844, 
rs12029406) polymorphisms and the risk of pancreatic cancer. 
The analysis showed that the GA or AA genotype reduced the 
risk of pancreatic cancer and the A allele reduced the risk to 
0.85 compared with the rs3790843 polymorphism and the TC 
or CC genotype, which played a similar role in the rs3790844 
polymorphism, and the C allele reduced the risk to 0.78. More-
over, the TC or TT genotype of rs12029406 could also protect 
from pancreatic cancer and the T allele reduced the risk to 
0.87. The largest value of I2 was 16.9% (,25%), which means 
that no heterogeneity was found in all studies. Meanwhile, no 
abnormality was found in sensitivity analysis.
Limitations
There were some limitations in our meta-analysis which 
might have affected the final outcomes. First, the study 
was based on unadjusted OR values, which did not contain 
the well-known predisposing factors of pancreatic cancer, 
such as age, sex, alcohol, smoking, diabetes and chronic 
pancreatitis. Second, we lacked data from non-Caucasian 
populations in Africa in the subgroup analysis for ethnicity. 
Finally, different genotypic methods (Fluidgm, TapMan, 
KASPar and so on) could also have an impact on the out-
come. More researches are needed to further analyze the 
association between NR5A2 polymorphism and the risk of 
pancreatic cancer.
Conclusion
Our study showed that the NR5RA rs3790843, rs3790844 
and rs12029406 polymorphisms were favorable factors in 
the risk of pancreatic cancer and were more protective in 
Caucasian population. If the mechanism behind this could be 
discovered by further research, hopefully, it will become a 
target for future personalized treatment of pancreatic cancer. 
Due to the limitations shown in this analysis, larger sample 
size and diverse studies are needed to confirm our results.
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Figure S3 subgroup analysis of sample size for nr5a2 rs3790843 g.a polymorphism and pancreatic cancer risk.
Notes: (A) ga vs gg; (B) ga+aa vs gg; (C) a vs g. n, the total sample size is smaller than 1,000; Y, the total sample size is larger than 1,000.
Abbreviation: Or, odds ratio.
Figure S2 subgroup analysis of type of control source for nr5a2 rs3790844 T.c polymorphism and pancreatic cancer risk.
Notes: (A) cc vs TT; (B) cc vs TT+cT; (C) c vs T. Weights are from random-effects analysis.
Abbreviations: hB, hospital-based; Or, odds ratio; PB, population-based.
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effects analysis.
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Figure S5 (Continued)
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Figure S5 The sensitivity analysis of pancreatic cancer risk associated with nr5a2 polymorphism.
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